| Application: | Internal Medicine |
|---|---|
| Usage Mode: | For external use |
| Suitable for: | Elderly, Children, Adult |
| State: | Solid |
| Shape: | Powder |
| Type: | Organic Chemicals |
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Ceftriaxone Sodium Powder For Injection |
| Contains | Ceftriaxone 1gram; |
| Package | 1 vials/box or 1vial+1solution/box |
| Store | Below 30C |
| Application | Antibiotic |
|
Before instituting treatment with ceftriaxone for injection, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone for injection and the comparator. The potentially lower clinical cure rate of ceftriaxone for injection should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, *Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for injection, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for injection has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli.* *Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of ceftriaxone for injection may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone for injection has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection provides protection from most infections due to susceptible organisms throughout the course of the procedure. |
|
|
|
|
|
|
|
|
We are a pharmaceutical products supplier originating from China, having weathered nearly two decades of storms. Since our establishment in 2005, we have been deeply rooted in this land and have grown into a leading player in the industry through our deep understanding of the pharmaceutical industry and our rich experience.
Our business scope covers healthcare products, medical devices, and pharmaceuticals, and every product carries our commitment to quality and health. We know that health is a precious wealth for everyone, so we are dedicated to providing high-quality, reliable products and services to our customers, enabling them to enjoy the health assurance we bring.
Innovation is our core advantage, and we place emphasis on research and development to continuously explore new technologies and methods to meet the changing needs of our customers. We have a professional R&D team that keeps up with the latest developments in the pharmaceutical industry and converts the latest scientific research results into practical products to provide our customers with more advanced and effective solutions.
Looking to the future, we will continue to adhere to the business philosophy of "quality first, customer first" and continuously enhance our overall strength and core competitiveness. We will further expand our business scope and explore new market areas to provide more customers with high-quality pharmaceutical products and services. Meanwhile, we will also continue to strengthen our R&D innovation efforts and launch more innovative and practical products to contribute more to the cause of human health.
We believe that with our continuous efforts and expertise, we will be able to provide our customers with the best solutions and become their most trustworthy partners.
We are looking for coorperating partners all around the world. Contact us if you are pharmaceutical distrabuters or traders, or wholesalers in North Africa, South America, Southeast Asia or Europe.
|
Service we can provide: 1. Mixed container, we can mix different items in one container. 2. Quality control, before shipment, free sample for test. After shipment, keep sample for 3 years 3. Prompt shipment with professional documents 4. Packing as your request, with photo before shipment. DMS CHEMICAL PHARMACEUTICAL INC.LTD http://dmsdrugs.en.made-in-china.com/ |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}